Mayer Fishman

Summary

Affiliation: H. Lee Moffitt Cancer Center and Research Institute
Country: USA

Publications

  1. pmc Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments
    Shilpa Gupta
    Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Onco Targets Ther 4:79-96. 2011
  2. ncbi request reprint Targeted therapy of kidney cancer: keeping the art around the algorithms
    Mayer N Fishman
    Genitourinary Oncology Program, Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Control 20:222-32. 2013
  3. doi request reprint A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer
    Mayer Fishman
    Moffitt Cancer Center, Department of Genitourinary Oncology, Tampa, FL 33612, USA
    Expert Opin Biol Ther 9:1565-75. 2009
  4. pmc Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies
    Mayer N Fishman
    Departments of Genitourinary Oncology and Cutaneous Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Clin Cancer Res 17:7765-75. 2011
  5. doi request reprint Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma
    Steven E Finkelstein
    Immunotherapy Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Immunother 33:817-27. 2010
  6. ncbi request reprint Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma
    Mayer Fishman
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    J Immunother 31:72-80. 2008
  7. pmc Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer
    Je In Youn
    Departments of Immunology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Nat Immunol 14:211-20. 2013
  8. pmc Lipid accumulation and dendritic cell dysfunction in cancer
    Donna L Herber
    Department of Immunology, H Lee Moffitt Cancer Center, Tampa, Florida, USA
    Nat Med 16:880-6. 2010
  9. pmc All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients
    Noweeda Mirza
    H Lee Moffitt Cancer Center and the Department of Interdisciplinary Oncology, University of South Florida, Tampa, Florida 33612, USA
    Cancer Res 66:9299-307. 2006
  10. doi request reprint Sipuleucel-T: Prototype for development of anti-tumor vaccines
    Estrella Carballido
    Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Curr Oncol Rep 13:112-9. 2011

Research Grants

Collaborators

Detail Information

Publications24

  1. pmc Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments
    Shilpa Gupta
    Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Onco Targets Ther 4:79-96. 2011
    ..Sipuleucel-T therapy is appraised from clinician, patient and immunotherapeutic perspectives, with reference to the clinical data from the pivotal trial, the mechanism of action, and the treatment process...
  2. ncbi request reprint Targeted therapy of kidney cancer: keeping the art around the algorithms
    Mayer N Fishman
    Genitourinary Oncology Program, Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Control 20:222-32. 2013
    ..Interferon and interleukin 2 also are part of the treatment algorithms...
  3. doi request reprint A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer
    Mayer Fishman
    Moffitt Cancer Center, Department of Genitourinary Oncology, Tampa, FL 33612, USA
    Expert Opin Biol Ther 9:1565-75. 2009
    ..More recently DCvax brain, a product using a similar DC platform showed encouraging Phase I-II results and sipleucel-T, a prostatic acid phosphatase (PAP)-directed DC immunotherapy had positive Phase III results...
  4. pmc Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies
    Mayer N Fishman
    Departments of Genitourinary Oncology and Cutaneous Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Clin Cancer Res 17:7765-75. 2011
    ..We evaluated the safety, pharmacokinetics, and pharmacodynamics of ALT-801 in p53+/HLA-A*0201 patients with metastatic malignancies...
  5. doi request reprint Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma
    Steven E Finkelstein
    Immunotherapy Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    J Immunother 33:817-27. 2010
    ..Pretreatment assessment of DC phenotypic or maturational status may be a starting point to predicting response to high-dose IL-2 cytokine immunotherapy in patients with melanoma and kidney cancer...
  6. ncbi request reprint Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma
    Mayer Fishman
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33612, USA
    J Immunother 31:72-80. 2008
    ..Better outcomes could be logically associated to vaccine response (detectable lymphocytic infiltrates) or to random events that a single arm study design cannot address. This vaccine approach may merit further clinical development...
  7. pmc Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer
    Je In Youn
    Departments of Immunology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Nat Immunol 14:211-20. 2013
    ..These data demonstrate a new regulatory mechanism of myeloid cells in cancer...
  8. pmc Lipid accumulation and dendritic cell dysfunction in cancer
    Donna L Herber
    Department of Immunology, H Lee Moffitt Cancer Center, Tampa, Florida, USA
    Nat Med 16:880-6. 2010
    ..These findings suggest that immune responses in cancer can be improved by manipulating the lipid levels in DCs...
  9. pmc All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients
    Noweeda Mirza
    H Lee Moffitt Cancer Center and the Department of Interdisciplinary Oncology, University of South Florida, Tampa, Florida 33612, USA
    Cancer Res 66:9299-307. 2006
    ..ATRA treatment did not result in significant toxicity and it could be tested in therapeutic combination with cancer vaccines...
  10. doi request reprint Sipuleucel-T: Prototype for development of anti-tumor vaccines
    Estrella Carballido
    Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Curr Oncol Rep 13:112-9. 2011
    ..We discuss how this successful immunotherapy outcome challenges us to use it as a starting point for variations to or try to amplify practical anticancer progress within the antitumor vaccine paradigm...
  11. doi request reprint Cellular immunotherapy for soft tissue sarcomas
    Steven Eric Finkelstein
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Immunotherapy 4:283-90. 2012
    ..In this report, we review immunotherapeutic investigative strategies that are being developed, including several tumor vaccine, antigen vaccine and dendritic cell vaccine strategies...
  12. ncbi request reprint Specific antitumour vaccine for renal cancer
    Mayer Fishman
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Lancet 363:583-4. 2004
  13. pmc Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer
    Srinivas Nagaraj
    H Lee Moffitt Cancer Center, Tampa, Florida 33647, USA
    Clin Cancer Res 16:1812-23. 2010
    ..Myeloid-derived suppressor cells (MDSC) are one of the major factors responsible for immune suppression in cancer. Therefore, it would be important to identify effective therapeutic means to modulate these cells...
  14. ncbi request reprint Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial
    George R Simon
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center and Research Institute, University of South Florida, 12902 Magnolia Drive, SRB 2, Tampa, 33612 9416, USA
    Mol Cancer Ther 5:2130-7. 2006
    ..Here, we evaluated a sequence-specific administration of a topo I inhibitor followed by a topo II inhibitor...
  15. ncbi request reprint Phase II trial of thalidomide and daily oral dexamethasone for treatment of hormone refractory prostate cancer progressing after chemotherapy
    Silvia Romero
    Florida Cancer Specialists, Ft Myers, FL, 33901 8108, USA
    Urol Oncol 25:284-90. 2007
    ..Responses to monotherapy corticosteroid or thalidomide have been described in prostate cancer, in chemotherapy naïve subjects...
  16. ncbi request reprint Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells
    Yulia Nefedova
    H Lee Moffitt Cancer Center and University of South Florida, Tampa, Florida 33612, USA
    Cancer Res 67:11021-8. 2007
    ..This novel mechanism involves specific up-regulation of GSS and accumulation of GSH and could be used in developing and monitoring therapeutic application of ATRA...
  17. ncbi request reprint Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study
    Pamela Munster
    Experimental Therapeutics, Breast Medical Oncology Program, Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    J Clin Oncol 25:1979-85. 2007
    ....
  18. ncbi request reprint Surgery plus targeted therapy for renal cell carcinoma with isolated spermatic cord metastasis
    Jose J Correa
    Department of Urologic Oncology and Genitourinary Medical Oncology, H Lee Moffitt Cancer and Research Center, Tampa, FL 33612, USA
    Clin Genitourin Cancer 7:E101-3. 2009
    ..We present a case of renal cell carcinoma with metastasis to the ipsilateral spermatic cord. We report the clinical presentation and management of this case and review the scientific literature of this unusual case presentation...
  19. doi request reprint Effects of self-directed stress management training and home-based exercise on quality of life in cancer patients receiving chemotherapy: a randomized controlled trial
    Paul B Jacobsen
    Division of Population Science, Moffitt Cancer Center, Tampa, FL 33612, USA
    Psychooncology 22:1229-35. 2013
    ..The present study extends this work by evaluating separate and combined effects of stress management training and home-based exercise...
  20. doi request reprint Progress and contrasts of the development of tivozanib for therapy of kidney cancer
    Shilpa Gupta
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Expert Opin Pharmacother 12:2915-22. 2011
    ..There is a need to develop more potent and selective targeted agents for RCC therapy, which are more effective and have minimal off-target effects...
  21. ncbi request reprint Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study
    George R Simon
    Division of Thoracic Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Clin Cancer Res 12:4645-51. 2006
    ..In phase I studies with oral CI-1033, dose-limiting toxicities were primarily gastrointestinal, supporting the exploration of i.v. dosing to achieve optimal drug exposures by increasing bioavailability...
  22. pmc The histogenic origin of melanoma arising in respiratory epithelium of a teratomatous germ cell tumor of the mediastinum: an enigma unraveled from an unlikely source
    Patricia McNab
    University of South Florida College of Medicine, Tampa, FL, USA
    Int J Clin Exp Pathol 5:982-90. 2012
    ..This microscopic approach should bring to light the diversity of mixed germ cell tumors in addition to somatic malignancies with corresponding biologic potentials...
  23. ncbi request reprint Novel therapies for renal cell carcinoma--an update
    Mayer Fishman
    H Lee Moffitt Cancer Center and Research Institute, University of South Florida, MCC 4035, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Expert Opin Investig Drugs 12:593-609. 2003
    ..Although high percentage improvements in outcomes for metastatic RCC are not yet realised, the many fronts for scientific and clinical advances form some basis for optimism in the coming years...
  24. ncbi request reprint Immunotherapy of metastatic renal cell cancer
    Mayer Fishman
    Genitourinary Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 9:293-304. 2002
    ..The management of metastatic renal cancer remains a therapeutic challenge. Conventional cytotoxic chemotherapy is rarely effective, and the most promising approaches appear to lie in the field of immunotherapy...

Research Grants3